The Cooper Companies, Inc.
COOHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeThe Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. Valued at $13.99B, COO is a large-cap name in its sector. The company operates in two segments, CooperVision and CooperSurgical.
Market Cap
$13.99B
Beta
0.84
P/E (TTM)
61.82
P/E (Fwd)
14.33
EPS (TTM)
$1.16
EPS (Fwd)
$5.00
ROE
2.9%
ROA
2.5%
Cash
$138.8M
Total Debt
$2.73B
Free CF
$424.3M
52W Change
-1.3%
Annual Financials
Cash vs Debt
The Cooper Companies, Inc. carries $2.73B in total debt against $138.8M in cash reserves — debt is roughly 19.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. The company generates $424.3M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 2.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 2.5% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $3.31B (2022) to $4.09B (2025), reflecting a 24% increase over the period.
The Cooper Companies, Inc. carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. At over 50x earnings, COO carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. No single metric tells the full story. Reviewing COO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.